Search alternatives:
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
Showing 901 - 920 results of 59,271 for search '(( 5 we decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (mean decrease)))) ))', query time: 1.22s Refine Results
  1. 901
    Top 5 VADER words by TF-IDF before, during, and after Hurricane Dorian for each region.

    Top 5 VADER words by TF-IDF before, during, and after Hurricane Dorian for each region. by Krishna Bathina (12883820)

    Published 2022
    Save to List
    Saved in:
  2. 902
    Top 5 VADER words by normalized TF-IDF scores before, during, and after each hurricane.

    Top 5 VADER words by normalized TF-IDF scores before, during, and after each hurricane. by Krishna Bathina (12883820)

    Published 2022
    Save to List
    Saved in:
  3. 903
    Primary and secondary outcomes of the randomized clinical trial groups at 3 months and 12 months.

    Primary and secondary outcomes of the randomized clinical trial groups at 3 months and 12 months. by Teemu P. Hevonkorpi (11577571)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 904
    Baseline characteristics of 291 patients by randomization group.

    Baseline characteristics of 291 patients by randomization group. by Teemu P. Hevonkorpi (11577571)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 905
    Adverse events at 12-month follow-up by study group.

    Adverse events at 12-month follow-up by study group. by Teemu P. Hevonkorpi (11577571)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 906
    Participant flow diagram of the DRIFT trial.

    Participant flow diagram of the DRIFT trial. by Teemu P. Hevonkorpi (11577571)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 907
    Between-group differences of mean PRWE with 95% confidence intervals in primarily malaligned DRFs and early malaligned DRFs at 3-month and 12-month follow-up.

    Between-group differences of mean PRWE with 95% confidence intervals in primarily malaligned DRFs and early malaligned DRFs at 3-month and 12-month follow-up. by Teemu P. Hevonkorpi (11577571)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 908
    nanoDSF apparent melting points.

    nanoDSF apparent melting points. by Aleksi Sutinen (10039145)

    Published 2023
    Save to List
    Saved in:
  9. 909
    Fig 5 -

    Fig 5 - by Melissa K. Peckins (12042132)

    Published 2022
    Save to List
    Saved in:
  10. 910
    Acute exercise decreased plasma insulin and glucose.

    Acute exercise decreased plasma insulin and glucose. by Mirian A. Kurauti (3146271)

    Published 2016
    Save to List
    Saved in:
  11. 911
    Relative decreases in VP mean weights using -DDE against TP controls in nine laboratories (Lab)

    Relative decreases in VP mean weights using -DDE against TP controls in nine laboratories (Lab) by William Owens (20777)

    Published 2011
    Save to List
    Saved in:
  12. 912
    Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab)

    Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

    Published 2011
    Save to List
    Saved in:
  13. 913
    Mean pain interference overtime (baseline to 12 weeks).

    Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 914
    Mean pain severity overtime (baseline to 12 weeks).

    Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 915
    Fig 5 -

    Fig 5 - by Harshita Sharma (4836180)

    Published 2023
    Save to List
    Saved in:
  16. 916
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 917
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 918
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 919
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 920
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: